Header Logo

Connection

KAREN RABIN to Child

Back to Details
This is a "connection" page, showing publications KAREN RABIN has written about Child.
KAREN RABIN
Connection Strength
1.107
Child
  1. Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024 Jan 10; 42(2):218-227.
    View in: PubMed
    Score: 0.050
  2. Management of Down Syndrome-Associated Leukemias: A Review. JAMA Oncol. 2023 09 01; 9(9):1283-1290.
    View in: PubMed
    Score: 0.050
  3. Genetic Ancestry and Childhood Acute Lymphoblastic Leukemia Subtypes and Outcomes in the Genomic Era. JAMA Oncol. 2022 03 01; 8(3):342-343.
    View in: PubMed
    Score: 0.045
  4. Optimizing Targeted Therapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. JAMA Oncol. 2020 03 01; 6(3):333-334.
    View in: PubMed
    Score: 0.039
  5. Need for new thinking: Treatment of relapsed leukemia in children with Down syndrome. Pediatr Blood Cancer. 2019 06; 66(6):e27644.
    View in: PubMed
    Score: 0.036
  6. Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatr Blood Cancer. 2017 Sep; 64(9).
    View in: PubMed
    Score: 0.032
  7. Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Apr; 58(4):633-5.
    View in: PubMed
    Score: 0.022
  8. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Sep; 59(3):468-74.
    View in: PubMed
    Score: 0.022
  9. Malignancy in children with trisomy 21. Oncologist. 2009 Feb; 14(2):164-73.
    View in: PubMed
    Score: 0.018
  10. Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009 Mar; 144(6):930-2.
    View in: PubMed
    Score: 0.018
  11. Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res. 2009 Feb; 33(2):336-9.
    View in: PubMed
    Score: 0.017
  12. Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer. 2008 Aug; 51(2):171-7.
    View in: PubMed
    Score: 0.017
  13. Personalized care of pediatric cancer patients. Nestle Nutr Workshop Ser Pediatr Program. 2008; 62:173-85; discussion 185-8.
    View in: PubMed
    Score: 0.017
  14. Automated Electronic Health Record Data Extraction and Curation Using ExtractEHR. JCO Clin Cancer Inform. 2024 Nov; 8:e2400100.
    View in: PubMed
    Score: 0.014
  15. Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
    View in: PubMed
    Score: 0.013
  16. Cerebral Sinus Venous Thrombosis in Pediatric Acute Lymphoblastic Leukemia: Incidence, Clinical Characteristics, and Long-term Neurologic Outcomes. J Child Neurol. 2024 Nov; 39(13-14):494-499.
    View in: PubMed
    Score: 0.013
  17. Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia. J Clin Oncol. 2024 Oct 10; 42(29):3491-3503.
    View in: PubMed
    Score: 0.013
  18. Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
    View in: PubMed
    Score: 0.013
  19. Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 Apr; 38(4):720-728.
    View in: PubMed
    Score: 0.013
  20. Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
    View in: PubMed
    Score: 0.013
  21. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome. Blood Adv. 2023 11 14; 7(21):6532-6539.
    View in: PubMed
    Score: 0.013
  22. Racial and ethnic disparities in acuity of presentation among children with newly diagnosed acute leukemia. Pediatr Blood Cancer. 2024 Jan; 71(1):e30726.
    View in: PubMed
    Score: 0.013
  23. Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023 10 01; 108(10):2570-2581.
    View in: PubMed
    Score: 0.012
  24. Acute and chronic kidney injury during therapy for pediatric acute leukemia: A report from the Leukemia Electronic Abstraction of Records Network (LEARN). Pediatr Blood Cancer. 2023 Dec; 70(12):e30696.
    View in: PubMed
    Score: 0.012
  25. Children's Oncology Group blueprint for research: Acute lymphoblastic leukemia. Pediatr Blood Cancer. 2023 09; 70 Suppl 6:e30585.
    View in: PubMed
    Score: 0.012
  26. Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children's Oncology Group report. Blood. 2023 04 13; 141(15):1802-1811.
    View in: PubMed
    Score: 0.012
  27. Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. Leukemia. 2023 06; 37(6):1375-1378.
    View in: PubMed
    Score: 0.012
  28. Prognostic impact of pretreatment immunoglobulin clonal composition in pediatric B-lymphoblastic leukemia. Haematologica. 2023 03 01; 108(3):900-904.
    View in: PubMed
    Score: 0.012
  29. Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy. 2023 03; 43(3):205-214.
    View in: PubMed
    Score: 0.012
  30. Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia. Blood Adv. 2023 02 14; 7(3):422-435.
    View in: PubMed
    Score: 0.012
  31. Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. Lancet Haematol. 2023 Feb; 10(2):e129-e141.
    View in: PubMed
    Score: 0.012
  32. Ethnic-specific predictors of neurotoxicity among patients with pediatric acute lymphoblastic leukemia after high-dose methotrexate. Cancer. 2023 04 15; 129(8):1287-1294.
    View in: PubMed
    Score: 0.012
  33. Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy. Pediatr Blood Cancer. 2023 01; 70(1):e30062.
    View in: PubMed
    Score: 0.012
  34. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 11; 69(11):e29937.
    View in: PubMed
    Score: 0.012
  35. The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet. 2022 09; 54(9):1376-1389.
    View in: PubMed
    Score: 0.012
  36. Epigenome-wide association study of acute lymphoblastic leukemia in children with Down syndrome. Blood Adv. 2022 07 26; 6(14):4132-4136.
    View in: PubMed
    Score: 0.011
  37. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group. Lancet Haematol. 2022 Sep; 9(9):e678-e688.
    View in: PubMed
    Score: 0.011
  38. A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 05 01; 107(5):1185-1188.
    View in: PubMed
    Score: 0.011
  39. An updated assessment of 43,110 patients enrolled in the Childhood Cancer Research Network: A Children's Oncology Group report. Cancer. 2022 07 15; 128(14):2760-2767.
    View in: PubMed
    Score: 0.011
  40. Residence in a Latinx enclave and end-induction minimal residual disease positivity among children with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2022 Oct; 39(7):650-657.
    View in: PubMed
    Score: 0.011
  41. Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. Cancer. 2022 05 01; 128(9):1863-1870.
    View in: PubMed
    Score: 0.011
  42. Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. Leukemia. 2022 03; 36(3):648-655.
    View in: PubMed
    Score: 0.011
  43. Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 10 04; 11(1):19613.
    View in: PubMed
    Score: 0.011
  44. Association of Combined Focal 22q11.22 Deletion and IKZF1 Alterations With Outcomes in Childhood Acute Lymphoblastic Leukemia. JAMA Oncol. 2021 Oct 01; 7(10):1521-1528.
    View in: PubMed
    Score: 0.011
  45. An evidence-based, risk-adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies. Pediatr Blood Cancer. 2021 12; 68(12):e29228.
    View in: PubMed
    Score: 0.011
  46. Converging genetic and epigenetic drivers of paediatric acute lymphoblastic leukaemia identified by an information-theoretic analysis. Nat Biomed Eng. 2021 04; 5(4):360-376.
    View in: PubMed
    Score: 0.011
  47. Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. Pediatr Blood Cancer. 2021 08; 68(8):e29036.
    View in: PubMed
    Score: 0.010
  48. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 04; 68(4):e28929.
    View in: PubMed
    Score: 0.010
  49. Molecular basis of ETV6-mediated predisposition to childhood acute lymphoblastic leukemia. Blood. 2021 01 21; 137(3):364-373.
    View in: PubMed
    Score: 0.010
  50. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. J Clin Oncol. 2021 05 01; 39(13):1437-1447.
    View in: PubMed
    Score: 0.010
  51. The relationship between chronic health conditions and cognitive deficits in children, adolescents, and young adults with down syndrome: A systematic review. PLoS One. 2020; 15(9):e0239040.
    View in: PubMed
    Score: 0.010
  52. Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 10 01; 38(28):3282-3293.
    View in: PubMed
    Score: 0.010
  53. Area deprivation is associated with poorer overall survival in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2020 09; 67(9):e28525.
    View in: PubMed
    Score: 0.010
  54. Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. J Clin Oncol. 2020 08 10; 38(23):2628-2638.
    View in: PubMed
    Score: 0.010
  55. Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. Anticancer Res. 2020 Jun; 40(6):3147-3153.
    View in: PubMed
    Score: 0.010
  56. Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2020 06 08; 37(6):867-882.e12.
    View in: PubMed
    Score: 0.010
  57. Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatr Blood Cancer. 2021 09; 68(9):e28315.
    View in: PubMed
    Score: 0.010
  58. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020 07; 34(7):1741-1750.
    View in: PubMed
    Score: 0.010
  59. Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. J Natl Cancer Inst. 2019 12 01; 111(12):1350-1357.
    View in: PubMed
    Score: 0.010
  60. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. Cancer. 2020 02 01; 126(3):593-601.
    View in: PubMed
    Score: 0.009
  61. Metabolomic profiling identifies pathways associated with minimal residual disease in childhood acute lymphoblastic leukaemia. EBioMedicine. 2019 Oct; 48:49-57.
    View in: PubMed
    Score: 0.009
  62. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood. 2019 10 10; 134(15):1227-1237.
    View in: PubMed
    Score: 0.009
  63. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Adv. 2019 06 11; 3(11):1647-1656.
    View in: PubMed
    Score: 0.009
  64. Maternal Residential Proximity to Major Roadways and the Risk of Childhood Acute Leukemia: A Population-Based Case-Control Study in Texas, 1995-2011. Int J Environ Res Public Health. 2019 06 07; 16(11).
    View in: PubMed
    Score: 0.009
  65. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat Genet. 2019 02; 51(2):296-307.
    View in: PubMed
    Score: 0.009
  66. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica. 2019 05; 104(5):986-992.
    View in: PubMed
    Score: 0.009
  67. Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol. 2018 10 10; 36(29):2926-2934.
    View in: PubMed
    Score: 0.009
  68. Maternal folate genes and aberrant DNA hypermethylation in pediatric acute lymphoblastic leukemia. PLoS One. 2018; 13(5):e0197408.
    View in: PubMed
    Score: 0.009
  69. An overview of disparities in childhood cancer: Report on the Inaugural Symposium on Childhood Cancer Health Disparities, Houston, Texas, 2016. Pediatr Hematol Oncol. 2018 Mar; 35(2):95-110.
    View in: PubMed
    Score: 0.009
  70. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018 07 19; 132(3):264-276.
    View in: PubMed
    Score: 0.009
  71. Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy. Blood. 2018 05 31; 131(22):2466-2474.
    View in: PubMed
    Score: 0.009
  72. Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial. J Clin Oncol. 2018 05 01; 36(13):1330-1338.
    View in: PubMed
    Score: 0.008
  73. Family-based exome-wide association study of childhood acute lymphoblastic leukemia among Hispanics confirms role of ARID5B in susceptibility. PLoS One. 2017; 12(8):e0180488.
    View in: PubMed
    Score: 0.008
  74. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. Blood. 2017 06 22; 129(25):3352-3361.
    View in: PubMed
    Score: 0.008
  75. Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathway. Leukemia. 2017 06; 31(6):1314-1324.
    View in: PubMed
    Score: 0.008
  76. Family-based exome-wide assessment of maternal genetic effects on susceptibility to childhood B-cell acute lymphoblastic leukemia in hispanics. Cancer. 2016 Dec 01; 122(23):3697-3704.
    View in: PubMed
    Score: 0.008
  77. The TGF-?/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016 Apr; 30(4):800-11.
    View in: PubMed
    Score: 0.007
  78. Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients. Am J Clin Pathol. 2015 Aug; 144(2):263-70.
    View in: PubMed
    Score: 0.007
  79. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62(10):1717-24.
    View in: PubMed
    Score: 0.007
  80. Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. Cancer Genet. 2015 Jan-Feb; 208(1-2):1-18.
    View in: PubMed
    Score: 0.007
  81. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7.
    View in: PubMed
    Score: 0.006
  82. Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy. Clin Cancer Res. 2013 Sep 15; 19(18):5079-91.
    View in: PubMed
    Score: 0.006
  83. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23.
    View in: PubMed
    Score: 0.006
  84. Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.